🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
After the Mother of All Deals: A Blueprint for the Ireland-India Pharmaceutical Corridor Under the EU-India FTA ◆ The UK-India CETA: A Deep Dive into Bilateral Pharmaceutical Value Chains, API Trade, and Medicine Price Trajectories ◆ Bilateral Breakthrough: How the Historic UK-India Free Trade Agreement Transforms Life Sciences and Key Trade Sectors ◆ Normalization or Correction? Ireland’s Goods Exports Drop 29% in May as Pharma Surplus Narrows ◆ Pilot Photonics Secures €10.4 Million EIC Accelerator Funding to Scale Deeptech Photonic Chips ◆ Intel Announces €5 Billion ($5.7 Billion) AI-Driven Semiconductor Expansion at Leixlip, Kildare ◆ University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre ◆ Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 ◆ After the Mother of All Deals: A Blueprint for the Ireland-India Pharmaceutical Corridor Under the EU-India FTA ◆ The UK-India CETA: A Deep Dive into Bilateral Pharmaceutical Value Chains, API Trade, and Medicine Price Trajectories ◆ Bilateral Breakthrough: How the Historic UK-India Free Trade Agreement Transforms Life Sciences and Key Trade Sectors ◆ Normalization or Correction? Ireland’s Goods Exports Drop 29% in May as Pharma Surplus Narrows ◆ Pilot Photonics Secures €10.4 Million EIC Accelerator Funding to Scale Deeptech Photonic Chips ◆ Intel Announces €5 Billion ($5.7 Billion) AI-Driven Semiconductor Expansion at Leixlip, Kildare ◆ University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre ◆ Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 ◆
Updated 21 Jul 2026 · ClinicalTrials.gov

Acute Myeloid Leukemia Trials in Ireland

← All Irish trials

Every active and recruiting clinical study with an Irish site — searchable by condition, sponsor, phase and location. Refreshed daily from the ClinicalTrials.gov registry.

0
Recruiting now
2
Active studies
Active Phase 3
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen Nederland · started 2019-12-20
📍 Cork · Dublin · Galway · Limerick
NCT04027309 on ClinicalTrials.gov ↗
Active Phase 3
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen Nederland · started 2019-03-01
📍 Cork · Dublin · Galway
NCT03839771 on ClinicalTrials.gov ↗
No trials match your search.

Browse by location

Dublin · 81 Galway · 24 Cork · 19 Limerick · 8 Drogheda · 4 Crumlin · 3 Waterford · 3 Abbotstown · 2 Manorhamilton · 2 Sligo · 2 Beaumont · 2 Tallaght · 1

Browse by condition

Ulcerative Colitis · 4 Amyotrophic Lateral Sclerosis · 3 Cancer · 3 Crohn's Disease · 3 Mantle Cell Lymphoma · 2 Progressive Pulmonary Fibrosis · 2 Breast Cancer · 2 Multiple Myeloma · 2 Obesity · 2 Acute Myeloid Leukemia · 2 Myelodysplastic Syndrome With Exc… · 2 Breast Neoplasms · 2 Coronary Artery Disease (CAD) · 2 Heart Failure NYHA Class III · 2 Hypertension · 2 Vascular Diseases · 2
Cite this page

Priya Life Science (2026). Clinical Trials in Ireland Tracker. Available at: https://priyalifescience.com/clinical-trials-ireland/condition/acute-myeloid-leukemia (Accessed: 21 July 2026).

Embed this data ↗

Source: ClinicalTrials.gov, U.S. National Library of Medicine — studies listing at least one Irish site, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician. For trials across the wider EU, see our EU Clinical Trials Tracker.